FRISCO, Texas and TEMPE, Ariz., Jan. 16, 2026 /PRNewswire/ — AllyGPO® and BioCareSD®, a strategic partnership serving community-based specialty practices, todayFRISCO, Texas and TEMPE, Ariz., Jan. 16, 2026 /PRNewswire/ — AllyGPO® and BioCareSD®, a strategic partnership serving community-based specialty practices, today

AllyGPO and BioCareSD Welcome Retina Associates of Cleveland, Highlighting the Market Need for New Transparent, Technology-Forward Options

2026/01/16 21:32
Okuma süresi: 4 dk

FRISCO, Texas and TEMPE, Ariz., Jan. 16, 2026 /PRNewswire/ — AllyGPO® and BioCareSD®, a strategic partnership serving community-based specialty practices, today announced that Retina Associates of Cleveland, Inc (RACI) has selected BioCareSD for specialty distribution (SD) and AllyGPO for group purchasing organization (GPO) services. This relationship expands AllyGPO and BioCareSD’s growing national footprint in community retina and reflects increasing demand for alternative GPO and SD options that offer more transparent, technology-enabled drug management.

Founded in 1974 and celebrating more than 50 years of patient care, RACI is widely regarded as one of Ohio’s premier retina specialty practices. The practice is known for its leadership in clinical research and expertise in advanced treatments for age-related macular degeneration, diabetic retinopathy, retinal tears and detachments, and other complex retinal conditions.

“Maintaining our independence is central to how RACI cares for patients, and we value partners who support this,” said President of RACI David G. Miller, MD. “BioCareSD and AllyGPO, through consistent actions and collaboration, have demonstrated their genuine commitment to preserving community retina practice independence in meaningful, practical ways. Choosing to partner with them enables RACI to better manage day-to-day operational and financial demands while securing long-term resilience with more efficient workflows and greater visibility from data-driven analytics.”

AllyGPO and BioCareSD provide RACI with high-touch specialty distribution and GPO services designed specifically for modern community retina practices. Key considerations in RACI’s decision included supply reliability, transparency in drug pricing, more timely, accurate GPO contract rebates, and responsive, consultative support from a dedicated retina team that works closely with clinical and administrative teams.

Another differentiator was AllyGPO and BioCareSD’s technology-forward approach, including AllyIQ®, AllyGPO’s comprehensive specialty drug management platform. By integrating data from practices’ core operational systems and BioCareSD’s ordering site, AllyIQ supports informed decision making with clear, actionable insights into purchasing, inventory, and utilization.

“RACI exemplifies the kind of physician-led practice that AllyGPO was built to serve,” remarked Brian Ansay, CEO of AllyGPO. “Our role as a GPO is to provide insight and hands-on support that helps members navigate complexity, confidently make data-driven decisions, and firmly remain in control of their future.”

“Retina Associates of Cleveland is a highly respected practice with a longstanding reputation for clinical excellence and physician leadership,” said Jennifer Waters, SVP of Retina at BioCareSD. “Their decision to partner with us reinforces that the market is seeking more transparent, flexible, and technology-enabled distribution and GPO partners built specifically around the needs of community retina practices.” 

The addition of RACI reflects AllyGPO and BioCareSD’s continued growth in community retina, as practices seek support in navigating rising drug costs, payer pressures, new biosimilar introductions, increasing administrative complexity, and distributors’ acquisition of practices. To learn more, visit www.NewRetinaPartner.com.

About Retina Associates of Cleveland, Inc.
Retina Associates of Cleveland, Inc (RACI) is the largest retina practice in Ohio. Since 1974, the practice has striven to improve the quality of life for every patient by preserving their best vision possible. With 17 retinal specialists, 13 northeast Ohio locations, and continual clinical trials, the community has access to world-renowned expert retinal care.

About AllyGPO
AllyGPO is a tech-forward group purchasing organization empowering community practices to operate more efficiently, improve practice economics, and remain independent through AllyRetina, its dedicated retina service, and AllyIQ®, its comprehensive drug management platform combining inventory management, GPO contract optimization, and advanced analytics. www.AllyGPO.com.

About BioCareSD
BioCareSD, a BioCare company, is a national specialty distributor with over 40 years of experience delivering life-changing specialty therapies. Committed to redefining specialty distribution, BioCareSD focuses on trust, transparency, and operational excellence. The company provides high-touch, personalized service through a dedicated support team and 24/7/365 customer care. Its distribution model and expanding portfolio support partners in delivering care. www.biocaresd.com.

Media Contact:
Dara Shulman
407766@email4pr.com
866-255-9476

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/allygpo-and-biocaresd-welcome-retina-associates-of-cleveland-highlighting-the-market-need-for-new-transparent-technology-forward-options-302663422.html

SOURCE AllyGPO and BioCareSD

Piyasa Fırsatı
Stader Logosu
Stader Fiyatı(SD)
$0.1574
$0.1574$0.1574
-0.31%
USD
Stader (SD) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen service@support.mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

ETH Exit Queue Gridlocks As Validators Pile Up

ETH Exit Queue Gridlocks As Validators Pile Up

The post ETH Exit Queue Gridlocks As Validators Pile Up appeared on BitcoinEthereumNews.com. Welcome to The Protocol, CoinDesk’s weekly wrap of the most important stories in cryptocurrency tech development. I’m Margaux Nijkerk, a reporter at CoinDesk. In this issue: Ethereum Faces Validator Bottleneck With 2.5M ETH Awaiting Exit Is Ethereum’s DeFi Future on L2s? Liquidity, Innovation Say Perhaps Yes Ethereum Foundation Starts New AI Team to Support Agentic Payments American Express Introduces Blockchain-Based ‘Travel Stamps’ Network News ETHEREUM VALIDATOR EXIT QUEUE FACES BOTTLENECK: Ethereum’s proof-of-stake system is facing its largest test yet. As of mid-September, roughly 2.5 million ETH — valued at roughly $11.25 billion — is waiting to leave the validator set, according to validator queue dashboards. The backlog pushed exit wait times to more than 46 days on Sept. 14, the longest in Ethereum’s short staking history, dashboards show. The last peak, in August, put the exit queue at 18 days. The initial spark came on Sept. 9, when Kiln, a large infrastructure provider, chose to exit all of its validators as a safety precaution. The move, triggered by recent security incidents including the NPM supply-chain attack and the SwissBorg breach, pushed around 1.6 million ETH into the queue at once. Though unrelated to Ethereum’s staking protocol itself, the hacks rattled confidence enough for Kiln to hit pause, highlighting how events in the broader crypto ecosystem can cascade into Ethereum’s validator dynamics. In a blog post from staking provider Figment, Senior Analyst Benjamin Thalman noted that the current exit queue build up isn’t only about security. After ETH has rallied more than 160% since April, some stakers are simply taking profits. Others, especially institutional players, are shifting their portfolios’ exposure. At the same time, the number of validators entering the Ethereum staking ecosystem has been steadily rising. Ethereum’s churn limit, which is a protocol safeguard that caps how many validators can…
Paylaş
BitcoinEthereumNews2025/09/18 15:15
TheWell Bioscience Launches VitroPrime™ 3D Culture and Imaging Plate for Organoid and 3D Cell Culture Workflows

TheWell Bioscience Launches VitroPrime™ 3D Culture and Imaging Plate for Organoid and 3D Cell Culture Workflows

A new in-plate, zero-disruption design enables reproducible organoid culture, downstream processing, and high-resolution imaging in a single 3D cell culture plate
Paylaş
AI Journal2026/02/09 22:02
Tom Lee Linked BitMine Scoops Up $82 Million in Ethereum as Institutional Appetite Heats Up

Tom Lee Linked BitMine Scoops Up $82 Million in Ethereum as Institutional Appetite Heats Up

Tom Lee–Backed BitMine Makes $82 Million Ethereum Purchase, Signaling Growing Institutional Confidence BitMine, a crypto-focused firm associated with veteran ma
Paylaş
Hokanews2026/02/09 22:08